TRPV1 and Miyoshi myopathy: In light of data from 600 patients, genetic factors (ABCB1/TRPV1/UGT2B7) may differentiate the response; in practice, consider documenting the phenotypic response and (when available) panel pharmacogenetic testing during long-term MM treatment [74].